Pfizer, Inc. (NYSE:PFE) – Investment analysts at Leerink Swann dropped their Q4 2017 EPS estimates for shares of Pfizer in a report released on Monday. Leerink Swann analyst S. Fernandez now forecasts that the biopharmaceutical company will post earnings per share of $0.55 for the quarter, down from their previous estimate of $0.59.

PFE has been the topic of several other research reports. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Jefferies Group LLC set a $38.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Barclays PLC set a $38.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. Pfizer presently has an average rating of “Hold” and an average target price of $38.26.

WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/24/brokers-offer-predictions-for-pfizer-inc-s-q4-2017-earnings-pfe.html.

Shares of Pfizer (NYSE:PFE) opened at 36.40 on Tuesday. The firm’s 50-day moving average price is $35.63 and its 200-day moving average price is $33.84. The firm has a market cap of $216.48 billion, a PE ratio of 26.63 and a beta of 1.00. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.78.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the firm posted $0.64 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year.

Large investors have recently made changes to their positions in the stock. Shine Investment Advisory Services Inc. acquired a new stake in Pfizer in the second quarter valued at about $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in Pfizer in the second quarter valued at about $103,000. D. Scott Neal Inc. lifted its position in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC acquired a new stake in Pfizer in the first quarter valued at about $121,000. Finally, Herndon Capital Management LLC acquired a new stake in Pfizer in the second quarter valued at about $120,000. Hedge funds and other institutional investors own 69.00% of the company’s stock.

In related news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the sale, the insider now owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total transaction of $249,900.00. Following the completion of the sale, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last 90 days, insiders sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by insiders.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.52%. Pfizer’s payout ratio is currently 94.12%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Earnings History and Estimates for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.